Edit
Celator Pharmaceuticals, Inc.
http://www.celatorpharma.com/Last activity: 01.05.2013
Active - Reference to Jazz Pharmaceuticals
Development of proprietary fixed dose combinations of chemotherapeutic agents for cancer treatment
Total raised: $57.5M
Investors 1
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.05.2013 | - | $32.5M | - |
| 30.12.2011 | - | $5M | - |
| 01.09.2010 | Series D | $20M | - |
Mentions in press and media 6
| Date | Title | Description |
| 01.05.2013 | Celator offers disruptive approach to chemo treatment options for acute myeloid leukemia | The Princeton, New Jersey-based treatment developer’s phase 3 clinical study will be a 300 patient, randomized, controlled study comparing CPX-351 to conventional cytarabine and daunorubicin therapy with a primary endpoint of overall surviv... |
| 01.05.2013 | Celator Pharmaceuticals Raises $32.5M | PRINCETON, NJ, Clinical-stage biopharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has raised $32.5 million >> Click here for more funding data on Celator Pharmaceuticals &... |
| 30.12.2011 | Celator Pharmaceuticals raising $5 million for cancer treatments | The Celator’s approach to cancer treatment is based on a synergistic ratio of drugs to improve tumor cell kill and locks the synergistic ratio in a drug-delivery vehicle to maintain the ratio in patients, according to its website. The goal ... |
| 01.09.2010 | Celator Pharmaceuticals Raises $20M in Series D Private Equity Financing | Celator Pharmaceuticals, Inc., a Princeton, NJ-based pharmaceutical company developing new therapies to treat cancer, raised $20m in a Series D private equity financing. The new capital will be used to support completion of ongoing clinical... |
| - | Celator offers disruptive approach to chemo treatment options for acute myeloid leukemia | A drug developer has done a final closing for its latest financing round to advance its new twist on chemotherapy treatment for 60- to 75-year-old patients with secondary acute myeloid leukemia through phase 3 clinical trials. Celator Pharm... |
| - | Celator Pharmaceuticals raising $5 million for cancer treatments | Celator Pharmaceuticals, a drug development company, is raising $5 million as its drug therapy for acute myeloid leukemia moves through phase 2 clinical trials. In its latest financing round, the company, which has offices in Princeton, New... |